JP2008540394A5 - - Google Patents

Download PDF

Info

Publication number
JP2008540394A5
JP2008540394A5 JP2008509529A JP2008509529A JP2008540394A5 JP 2008540394 A5 JP2008540394 A5 JP 2008540394A5 JP 2008509529 A JP2008509529 A JP 2008509529A JP 2008509529 A JP2008509529 A JP 2008509529A JP 2008540394 A5 JP2008540394 A5 JP 2008540394A5
Authority
JP
Japan
Prior art keywords
group
compound
pharmaceutical composition
carboxamide
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008509529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540394A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2006/001164 external-priority patent/WO2006117668A1/en
Publication of JP2008540394A publication Critical patent/JP2008540394A/ja
Publication of JP2008540394A5 publication Critical patent/JP2008540394A5/ja
Withdrawn legal-status Critical Current

Links

JP2008509529A 2005-05-04 2006-05-04 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用 Withdrawn JP2008540394A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67735105P 2005-05-04 2005-05-04
US67735005P 2005-05-04 2005-05-04
SE0501045 2005-05-04
SE0501044 2005-05-04
PCT/IB2006/001164 WO2006117668A1 (en) 2005-05-04 2006-05-04 Fatty acid analogues, i.e. dha derivatives for uses as a medicament

Publications (2)

Publication Number Publication Date
JP2008540394A JP2008540394A (ja) 2008-11-20
JP2008540394A5 true JP2008540394A5 (enExample) 2009-05-21

Family

ID=43955576

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008509528A Expired - Fee Related JP5337479B2 (ja) 2005-05-04 2006-05-04 新規化合物
JP2008509529A Withdrawn JP2008540394A (ja) 2005-05-04 2006-05-04 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008509528A Expired - Fee Related JP5337479B2 (ja) 2005-05-04 2006-05-04 新規化合物

Country Status (9)

Country Link
US (4) US7550613B2 (enExample)
EP (2) EP1888727B1 (enExample)
JP (2) JP5337479B2 (enExample)
CN (2) CN102050720B (enExample)
AU (1) AU2006242914B2 (enExample)
BR (1) BRPI0611159A2 (enExample)
CA (1) CA2607247C (enExample)
IN (1) IN2007CH04959A (enExample)
WO (2) WO2006117664A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
JP5337479B2 (ja) * 2005-05-04 2013-11-06 プロノヴァ・バイオファーマ・ノルゲ・アーエス 新規化合物
US20070032548A1 (en) * 2005-07-08 2007-02-08 Ellis Lorie A Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
WO2008063772A2 (en) * 2006-10-13 2008-05-29 The Brigham And Women's Hospital Inc. Resolvin d series and protectin d1 mitigate acute kidney injury
EP2094640A4 (en) 2006-11-01 2015-05-20 Pronova Biopharma Norge As ALPHA-SUBSTITUTED OMEGA-3 LIPIDS WHICH ARE ACTIVATORS OR MODULATORS OF THE PEROXISOMPROLIPATOR ACTOR-ACTIVATED RECEPTOR (PPAR)
US20100240616A1 (en) * 2006-11-01 2010-09-23 Anne Kristin Holmeide Novel lipid compounds
AU2008215077B2 (en) 2007-02-15 2012-08-23 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
ES2704439T3 (es) 2007-03-20 2019-03-18 Scf Pharma Inc Composiciones que comprenden monoglicéridos de ácidos grasos poliinsaturados o derivados de los mismos y usos de los mismos
WO2009056983A1 (en) * 2007-10-31 2009-05-07 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
EP2217224B1 (en) 2007-11-09 2019-05-08 Basf As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
WO2009134147A1 (en) * 2008-05-02 2009-11-05 Pronova Biopharma Norge As Lipid compositions containing derivatives of epa and dha an their use thereof
WO2009149496A1 (en) * 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
NZ807894A (en) 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EA021177B1 (ru) 2009-05-08 2015-04-30 Пронова Биофарма Норге Ас Полиненасыщенные жирные кислоты для лечения заболеваний, связанных с сердечно-сосудистыми, метаболическими и воспалительными заболеваниями
EP2248798A1 (en) 2009-05-08 2010-11-10 Pronova BioPharma Norge AS Novel lipid compounds
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
WO2011149766A2 (en) * 2010-05-23 2011-12-01 Jingxuan Kang Lipid-tailored pharmaceutical agents
ES2618604T3 (es) 2010-11-05 2017-06-21 Pronova Biopharma Norge As Métodos de tratamiento usando compuestos lipídicos
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en) * 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
WO2012112520A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. A formulations comprising omega 3 fatty acids and an anti obesity agent for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics
JP6399655B2 (ja) 2012-01-06 2018-10-03 オムセラ・ファーマシューティカルズ・インコーポレイテッド 遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物
US20150133551A1 (en) 2012-05-03 2015-05-14 Beth Israel Deaconess Medical Center, Inc. Lipids That Increase Insulin Sensitivity And Methods Of Using The Same
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
AU2013371074B2 (en) * 2012-12-24 2018-07-26 Qualitas Health Inc. Eicosapentaenoic acid (EPA) formulations
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
CA2942709C (en) * 2013-03-15 2021-04-06 Beth Israel Deaconess Medical Center, Inc. Lipids that increase insulin sensitivity and methods of using the same
JP5870952B2 (ja) * 2013-03-25 2016-03-01 富士ゼロックス株式会社 データ処理装置およびプログラム
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
BR112016029476A2 (pt) 2014-06-18 2017-08-22 Thetis Pharmaceuticals Llc complexos de aminoácido mineral de agentes ativos
KR102644400B1 (ko) 2015-04-28 2024-03-06 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
GB201521085D0 (en) * 2015-11-30 2016-01-13 Biozep As Use
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
WO2017214527A1 (en) 2016-06-10 2017-12-14 Beth Israel Deaconess Medical Center, Inc. Fatty acid esters of hydroxy fatty acids (fahfas) for use in the treatment of type 1 diabetes
CA3064132C (en) 2017-07-07 2024-06-04 Gregory Keyes Fatty acid derivatives and their use
EP3661600A4 (en) * 2017-10-23 2021-08-11 Epitracker, Inc. FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME
US11925614B2 (en) 2017-12-06 2024-03-12 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
WO2019153073A1 (en) 2018-02-07 2019-08-15 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
EP3787614B1 (en) 2018-05-03 2024-07-31 SCF Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions and use thereof for modulating a microbiota composition of a subject
JP2021525249A (ja) 2018-05-23 2021-09-24 エピトラッカー インコーポレイテッドＥｐｉｔｒａｃｋｅｒ， Ｉｎｃ． 加齢及び長期性の質に関連する状態の診断及び治療のための組成物及び方法
KR20230038594A (ko) 2018-09-24 2023-03-20 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
WO2020096935A1 (en) * 2018-11-05 2020-05-14 Pacific Industrial Development Corporation Method of making aei-type zeolites having a high silica to alumina molar ratio (sar)
WO2020146263A1 (en) 2019-01-09 2020-07-16 Epitracker, Inc. Compositions and methods for diagnosis and treatment of neurodegenerative diseases
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
EP4058141A4 (en) 2019-11-12 2023-11-22 Amarin Pharmaceuticals Ireland Limited METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH Atrial fibrillation and/or atrial flutter
CN111233694B (zh) * 2020-03-05 2021-05-11 浙江大学 具有降血脂作用的线性聚酮类化合物及其制备方法和应用
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
WO2023080939A1 (en) 2021-11-03 2023-05-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
CN119019255A (zh) * 2024-08-16 2024-11-26 合肥工业大学 一种dha分子活性探针及其制备方法和应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2836628A (en) 1955-10-17 1958-05-27 Monsanto Chemicals Unsaturated branched-chain alcohols and methods of preparing same
US4132719A (en) * 1978-04-20 1979-01-02 Mcneilab Inc. Dibromoalkylglycidic acid derivatives
US4264517A (en) * 1978-12-11 1981-04-28 G.D. Searle & Co. Alkylphenyl 5Z,8Z,11Z,14Z,17Z-eicosapentaenoates
JPS56108721A (en) 1980-01-30 1981-08-28 Maruzen Sekiyu Kagaku Kk Liquid branched-chain higher aliphatic 1-ol and its preparation
JPS5810079B2 (ja) 1981-03-09 1983-02-24 工業技術院長 微生物による混合イソプレノイド炭化水素のアルコ−ル誘導体の製造方法
JPS57149400A (en) * 1981-03-12 1982-09-14 Kureha Chemical Ind Co Ltd Manufacture of high purity long chain highly unsaturated fatty acid ester
JPS59204175A (ja) * 1983-04-28 1984-11-19 Terumo Corp ５―フルオロウラシル誘導体を有効成分とする血小板凝集抑制剤
JPS61103826A (ja) 1984-10-25 1986-05-22 Kao Corp 抗炎症剤
US4647685A (en) * 1985-04-25 1987-03-03 Eli Lilly And Company 2-alkoxy-1-((2-trialkylaminoethoxy)phosphinyloxy)-alkenes and alkynes, hydroxy inner salts
JPS6388159A (ja) * 1986-09-30 1988-04-19 Nippon Oil & Fats Co Ltd ドコサヘキサエン酸エステルの製造法
JPS6483031A (en) 1987-09-22 1989-03-28 Rikagaku Kenkyusho Synthesis of fluorohydrin
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
JPH05974A (ja) * 1991-06-21 1993-01-08 Sagami Chem Res Center ハロゲン化不飽和アルキル化合物及びその前駆体
US5422371A (en) 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
JPH06240289A (ja) 1992-06-09 1994-08-30 Bizen Kasei Kk ドコサヘキサエン酸エチルエステルを含有する脂肪酸エチルエステル混合物の製造方法
CN1082909A (zh) * 1993-01-03 1994-03-02 潘玉珍 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂
JPH06293789A (ja) * 1993-04-08 1994-10-21 Teijin Ltd 多価不飽和脂肪酸類配糖体およびその製造方法
JPH0753488A (ja) * 1993-08-10 1995-02-28 Aiwa:Kk ドコサヘキサエン酸誘導体
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JPH10195023A (ja) 1997-01-13 1998-07-28 Shiseido Co Ltd 新規高度不飽和脂肪酸エチルエステル
GB2323594A (en) 1997-03-25 1998-09-30 Victor Martin 2-amino-alkanoic acid derivatives, 2-amino alcohols and diamines
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
WO1999058120A1 (en) 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
JP4530311B2 (ja) 2000-07-13 2010-08-25 日本水産株式会社 リパーゼを用いたグリセライドの製造方法
JP2002180082A (ja) 2000-12-11 2002-06-26 Maruha Corp 摂取物
IT1320180B1 (it) * 2000-12-29 2003-11-26 Hunza Di Marazzita Maria Carme Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
JP3934968B2 (ja) 2002-03-25 2007-06-20 富士フイルム株式会社 色変換定義作成方法、色変換定義作成装置、および色変換定義作成プログラム
BR0309740A (pt) 2002-05-03 2005-02-22 Pronova Biocare As Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos
TW200412942A (en) 2002-08-06 2004-08-01 Abbott Lab Appetite control method
KR100951758B1 (ko) * 2002-08-07 2010-04-08 가오 가부시키가이샤 유지 조성물
NO319194B1 (no) * 2002-11-14 2005-06-27 Pronova Biocare As Lipase-katalysert forestringsfremgangsmate av marine oljer
JP2004182674A (ja) * 2002-12-05 2004-07-02 Kureha Chem Ind Co Ltd バニリル脂肪酸アミドを含む抗腫瘍医薬組成物
EP1596853A1 (en) 2003-02-12 2005-11-23 Galderma Research & Development, S.N.C. Compounds which are modulators of the ppar-type receptors and their use in cosmetic or pharmaceutical compositions
WO2004078166A2 (en) * 2003-03-05 2004-09-16 Solvay Pharmaceuticals Gmbh Use of omega-3-fatty acids in the treatment of diabetic patients
EP1605768A2 (en) 2003-03-27 2005-12-21 Suntory Limited Lipid-improving agent and composition containing lipid-improvimg agent
EP1466597A1 (en) * 2003-04-07 2004-10-13 Clinigenetics Use of dha esters to control or prevent cardiovascular diseases
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
JP5337479B2 (ja) * 2005-05-04 2013-11-06 プロノヴァ・バイオファーマ・ノルゲ・アーエス 新規化合物
GB0605900D0 (en) 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
ES2391305T3 (es) 2006-04-12 2012-11-23 Unilever N.V. Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel
EP2102139A2 (en) 2006-11-01 2009-09-23 Pronova Biopharma Norge AS Omega-3 lipid compounds
EP2094640A4 (en) 2006-11-01 2015-05-20 Pronova Biopharma Norge As ALPHA-SUBSTITUTED OMEGA-3 LIPIDS WHICH ARE ACTIVATORS OR MODULATORS OF THE PEROXISOMPROLIPATOR ACTOR-ACTIVATED RECEPTOR (PPAR)
HRP20180107T1 (hr) 2008-07-08 2018-03-09 Catabasis Pharmaceuticals, Inc. Acetilirani salicilati masnih kiselina i njihova upotreba

Similar Documents

Publication Publication Date Title
JP2008540394A5 (enExample)
CA2803558C (en) .omega.3 fatty acid compound preparation
US20250186384A1 (en) Compositions comprising 15-ohepa and methods of using the same
CA2607247A1 (en) .alpha.-substituted dha derivatives
EP2897595B1 (en) Omega -3 compositions
JP2013521310A5 (enExample)
JP2015520235A5 (enExample)
SI2443246T1 (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
SK13652003A3 (sk) Potenciácia terapeutického účinku mastných kyselín
ES2363964B1 (es) Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
HUP0200111A2 (hu) Esszenciális zsírsavak alkalmazása a cardiovascularis események megelőzésében alkalmazható gyógyszerkészítmények előállítására
JPH11209279A (ja) 体重減少および肥満処置の方法
JP2015143248A5 (enExample)
JP2011503057A5 (enExample)
JP2013507454A5 (enExample)
JP2020090508A5 (enExample)
JP2018515463A5 (enExample)
JP2016501248A5 (enExample)
CA2411568A1 (en) Compositions for the therapy of dementias
JP2020182497A5 (enExample)
JP2018510206A5 (enExample)
JP2020526485A5 (enExample)
JP2008522972A5 (enExample)
JP2008521877A5 (enExample)
JP2014513710A5 (enExample)